Urban–rural differences in the uptake of new oral bisphosphonate formulations

Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access

(2015) A. M. Burden et al.   OSTEOPOROSIS INTERNATIONAL

An overview on the treatment of postmenopausal osteoporosis

(2014) Sergio Setsuo Maeda et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data

(2014) Andrea M. Burden et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Eliminating the need for fasting with oral administration of bisphosphonates

(2013) Michael Pazianas et al.   Therapeutics and Clinical Risk Management

Randomized Trial of Alendronate Plus Vitamin D3 Versus Standard Care in Osteoporotic Postmenopausal Women with Vitamin D Insufficiency

(2011) Stuart H. Ralston et al.   CALCIFIED TISSUE INTERNATIONAL

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

(2011) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Gender, socioeconomic status, need or access? Differences in statin prescribing across urban, rural and remote Australia

(2009) Nigel Stocks et al.   Australian Journal of Rural Health

Impact of pharmaceutical representative visits on GPs' drug preferences

(2009) J. Sondergaard et al.   FAMILY PRACTICE

Patients’ Perceptions Of Generic Medications

(2009) William H. Shrank et al.   HEALTH AFFAIRS

Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials

(2009) M. M. Wilkes et al.   OSTEOPOROSIS INTERNATIONAL